Onconova Therapeutics (ONTX) Shares are Up 8.08%

Onconova Therapeutics (ONTX) has been under a strong bear grip, hence the stock is down -25.25% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 8.03% in the past 1 week. The stock has risen by 8.08% in the past week indicating that the buyers are active at lower levels, but the stock is down -24.48% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 6.11% and the 50-Day Moving Average is 24.79%. Onconova Therapeutics (NASDAQ:ONTX): stock turned positive on Friday. Though the stock opened at $3.5, the bulls momentum made the stock top out at $3.69 level for the day. The stock recorded a low of $3.28 and closed the trading day at $3.61, in the green by 3.44%. The total traded volume for the day was 499,336. The stock had closed at $3.49 in the previous days trading.


The company Insiders own 27.3% of Onconova Therapeutics shares according to the proxy statements. Institutional Investors own 71.24% of Onconova Therapeutics shares.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways important to cancer cells. It has three clinical-stage product candidates and many preclinical programs that target kinases, cellular metabolism or cell division. The Companys lead product candidate, rigosertib, is being tested as a single agent and in combination with azacitidine, in clinical trials of patients with myelodysplastic syndromes (MDS) and related cancers. The Company is continuing the Phase II portion of a clinical trial of rigosertib oral in combination with azacitidine for patients with MDS and acute myelogenous leukemia (AML).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.